PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Net income growth under 50% of TRVN's 21.70%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-22.93%
Negative yoy D&A while TRVN is 136.71%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
18.38%
Some yoy growth while TRVN is negative at -9.73%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-40.28%
Both cut yoy SBC, with TRVN at -12.42%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
112.09%
Less working capital growth vs. TRVN's 1127.94%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
AP growth of 86.72% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
300.21%
Lower 'other working capital' growth vs. TRVN's 1127.94%. David Dodd would see fewer unexpected short-term demands on cash.
-40.28%
Negative yoy while TRVN is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
17.79%
Operating cash flow growth below 50% of TRVN's 36.05%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
19.38%
CapEx growth well above TRVN's 27.90%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
Growth well above TRVN's 29.61%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
98.29%
Investing outflow well above TRVN's 45.14%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
684.38%
We slightly raise equity while TRVN is negative at -19.61%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.